Pandion Therapeutics Inc represents a commitment to transforming the lives of patients with autoimmune diseases. The company is driven by a patient-centric approach, focusing on developing innovative and targeted therapeutics. Pandion Therapeutics Inc values scientific excellence, leveraging cutting-edge technology and deep understanding of immunology to address the unmet medical needs of patients. The company is dedicated to fostering collaborations and partnerships to accelerate the development of novel treatments. With a strong emphasis on innovation, Pandion Therapeutics Inc aims to provide effective and personalized solutions for autoimmune diseases, improving patients' quality of life and overall well-being.

Pandion Therapeutics Inc is primarily present in the United States.

Pandion Therapeutics Inc has achieved significant milestones in its journey as a biotechnology company. Notably, the company completed its initial public offering (IPO) in July 2020, successfully raising funds to support its research and development efforts. In addition, Pandion Therapeutics has established strategic collaborations with leading pharmaceutical companies, such as Astellas Pharma Inc., which further validate its scientific approach and potential. The company has made progress in advancing its pipeline of novel drug candidates, aiming to address autoimmune and inflammatory diseases. Through its innovative research and strategic partnerships, Pandion Therapeutics Inc continues to make notable strides in the field of biotechnology.

Pandion Therapeutics Inc. is a biotechnology company specializing in the development of innovative antibody therapeutics. Founded in 2017, the company is headquartered in Watertown, Massachusetts. Pandion Therapeutics focuses on designing and developing bispecific antibody-based therapeutics to treat various autoimmune and inflammatory diseases. With a team of experienced scientists and industry professionals, the company leverages its proprietary platform to create novel molecules that target immune system components involved in these conditions. Pandion Therapeutics aims to provide effective and safe treatments to improve the lives of patients suffering from autoimmune disorders.

The main competitors of Pandion Therapeutics Inc in the market include other biotechnology companies focusing on autoimmune diseases and immunology therapies. These competitors may include names like Bristol-Myers Squibb, Eli Lilly and Company, Pfizer Inc., and Sanofi.

Pandion Therapeutics Inc is primarily active in the biotechnology industry.

The business model of Pandion Therapeutics Inc is focused on developing innovative therapeutics for patients with autoimmune and inflammatory diseases. The company employs a deep understanding of immunology and protein engineering to create modular biologics. These biologics are designed to target specific immune cells or pathways implicated in the diseases. By strategically partnering their technologies and expertise, Pandion Therapeutics aims to rapidly advance their pipeline and bring transformative treatments to patients in need. Pandion Therapeutics Inc's business model revolves around applying their scientific knowledge and innovative approach to develop novel therapies that have the potential to improve patient outcomes in the field of autoimmune and inflammatory diseases.

Pandion Therapeutics Коефіцієнт P/E становить -26,95.

Коефіцієнт виручки від продажу Pandion Therapeutics становить 0.

АлеАкції індекс якості для Pandion Therapeutics складає 2/10.

Дохід зараз не можна розрахувати для Pandion Therapeutics.

очікувана Pandion Therapeutics прибуток становить -59,03 млн. USD.

Pandion Therapeutics Inc. is a US-based biotechnology company that uses innovative technologies for researching and developing therapeutics against autoimmune diseases. Their business model focuses on the development and commercialization of therapeutic antibodies and targeted protein therapies that impact the human immune system. Pandion has developed innovative technologies to facilitate the discovery of therapeutic proteins, including methods for characterizing immune cells and identifying therapeutic target molecules. They have a central product portfolio of specialized antibodies and protein therapeutics that can be used to treat autoimmune diseases such as type 1 diabetes, rheumatoid arthritis, Crohn's disease, and multiple sclerosis. They also offer comprehensive services to support the research and development activities of biotech and pharmaceutical companies focused on antibody and protein development. Pandion utilizes strategic partnerships, collaborations, and mergers to strengthen their access to technologies and resources necessary for developing and expanding their pipeline of products and services, as well as the ability to effectively market their products worldwide. The company has achieved significant success and recently announced a merger with Merck & Co. Inc., a leading pharmaceutical company specializing in immuno-oncology and autoimmune therapeutics. This merger provides promising opportunities for further research and development of novel therapies against autoimmune diseases. Overall, Pandion Therapeutics Inc. has a strong business model with a promising portfolio of innovative products and services. They utilize a comprehensive technology platform and strategic partnerships to ensure they remain at the forefront of advanced therapy development. With a focus on antibody and protein therapeutics, they are well-positioned to develop and bring to market groundbreaking treatments for many of the world's most common autoimmune diseases.

Pandion Therapeutics виплачує дивіденд у розмірі 0 USD, розподілений на виплати протягом року.

Дивіденди для Pandion Therapeutics на даний момент не можуть бути розраховані, або компанія не виплачує дивіденди.

ISIN Pandion Therapeutics є US6983401067.

Тікер Pandion Therapeutics це PAND.

Протягом останніх 12 місяців компанія Pandion Therapeutics виплатила дивіденд у розмірі . Це відповідає приблизній дивідендній дохідності . Очікується, що протягом наступних 12 місяців Pandion Therapeutics виплатить дивіденд у розмірі 0 USD.

Дивідендна дохідність Pandion Therapeutics наразі становить .

Pandion Therapeutics виплачує дивіденди щоквартально. Вони виплачуються у місяцях .

Pandion Therapeutics протягом останніх 0 років щороку виплачував дивіденди.

На наступні 12 місяців очікується дивіденди у розмірі 0 USD. Це відповідає дивідендній дохідності 0 %.

Pandion Therapeutics призначається до сектора "Здоров'я".

Щоб отримати останній дивіденд від Pandion Therapeutics від 04.11.2024 у розмірі 0 USD, тобі потрібно було мати акцію в портфелі до дня Ex-Tag 04.11.2024.

Останню дивіденду було виплачено 04.11.2024.

У 2023 році компанія Pandion Therapeutics виплатила 0 USD у вигляді дивідендів.

Дивіденди Pandion Therapeutics виплачуються у USD.